Edgewise Therapeutics, Inc. (EWTX) SEC Filings — 2025
14 SEC filings for Edgewise Therapeutics, Inc. (EWTX) in 2025.
Filings
- Edgewise Therapeutics Files 8-K on Officer/Director Changes — 8-K · Nov 20, 2025
- Edgewise Therapeutics Files 8-K on Director Changes and Compensation — 8-K · Nov 10, 2025
- Edgewise Therapeutics' Q3 Loss Widens Amid R&D Surge — 10-Q · Nov 6, 2025
- Edgewise Therapeutics Files 8-K on Financials — 8-K · Aug 7, 2025
- Edgewise Losses Widen Amid R&D Push; No Revenue Reported — 10-Q · Aug 7, 2025
- Edgewise Therapeutics Files 8-K — 8-K · Jun 26, 2025
- Edgewise Therapeutics Files Proxy Statement Supplement — DEFA14A · May 14, 2025
- Edgewise Therapeutics Files 8-K on Financials — 8-K · May 8, 2025
- Edgewise Therapeutics Q1 2025: Assets $95.1M, Equity $95.2M — 10-Q · May 8, 2025
- Edgewise Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025
- Edgewise Therapeutics Schedules Annual Meeting, Seeks Director & Auditor Approval — 8-K · Apr 2, 2025
- Edgewise Therapeutics Files 8-K on Financials — 8-K · Mar 3, 2025
- Edgewise Therapeutics Files 2024 10-K — 10-K · Mar 3, 2025
- Edgewise Therapeutics Appoints New CMO, Adds Directors — 8-K · Jan 22, 2025